-
Je něco špatně v tomto záznamu ?
A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer
K. Liu, H. Zhao, X. Chen, R. Nicoletti, N. Vasdev, PK. Chiu, CF. Ng, T. Kawada, E. Laukhtina, K. Mori, T. Yanagisawa, D. D'Andrea, M. von Deimling, S. Albisinni, W. Krajewski, B. Pradere, F. Soria, M. Moschini, D. Enikeev, S. Shariat, A. Kamat,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- adjuvancia imunologická terapeutické užití aplikace a dávkování MeSH
- aplikace intravezikální MeSH
- BCG vakcína * terapeutické užití aplikace a dávkování MeSH
- invazivní růst nádoru MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- nádory močového měchýře neinvadující svalovinu * mortalita terapie MeSH
- nádory močového měchýře * mortalita terapie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Hongkong MeSH
BACKGROUND: Current European Association of Urology (EAU) guidelines support adjuvant intravesical Bacillus Calmette-Guérin (BCG) treatment after Transurethral Resection of Bladder Tumor (TURB) for intermediate- or high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients, aiming to reduce the risk of tumor recurrence. The quality of data, however, does not allow definitive conclusions on whether different strains and dosages of BCG have different efficacies on long-term survival outcomes. OBJECTIVE: To evaluate the long-term survival outcomes of different strains and dosages of BCG in patients with NMIBC. DESIGN, SETTING, AND PARTICIPANTS: All NMIBC patients treated with intravesical BCG therapy from 2001 to 2020 were identified using a territory-wide database in Hong Kong. INTERVENTION: BCG strains and dosages (Connaught strain 81 mg, Connaught strain 27 mg, Tokyo strain 80 mg, and Danish strain 30 mg) were retrieved from medical records. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. A multivariable Cox regression analysis was used to adjust potential confounding factors, and to estimate Hazard Ratio (HR) and 95% confidence interval (CI) of different BCG strains. A further subgroup analysis on adequate versus inadequate BCG treatment was performed. RESULTS AND LIMITATIONS: A total of 2602 NMIBC patients treated with intravesical BCG were identified. Among them, 1291 (49.6%) received Connaught strain 81 mg, 199 (7.6%) received Connaught strain 27 mg, 1014 (39.0%) received Tokyo strain, and 98 (3.8%) received Danish strain. The median follow-up was 11.0 years. No statistically significant differences in OS, CSS, RFS, and PFS were detected among the different groups. At the multivariable analysis, the Connaught strain 27 mg group was inferior to the Connaught strain 81 mg group in terms of OS (HR: 1.26, 95% CI: 1.05-1.51), CSS (HR: 1.69, 95% CI: 1.08-2.66), and PFS (HR: 1.86, 95% CI: 1.20-2.88). Adequate BCG treatment was associated with improved OS (HR: 0.82, 95% CI: 0.73-0.92), CSS (HR: 0.64, 95% CI: 0.47-0.86), RFS (HR: 0.80, 95% CI: 0.70-0.92), and PFS (HR: 0.52, 95% CI: 0.39-0.68). Among patients treated with adequate BCG, at the multivariable analysis the Connaught strain 27 mg group showed worse results than the Connaught strain 81 mg group in terms of CSS (HR: 1.93, 95% CI: 1.07-3.51). Compared with the Connaught strain 81 mg group, both Tokyo and Danish strains had similar survival outcomes in the whole cohort and the adequate BCG treatment subgroup. CONCLUSIONS: Our findings suggest that adequate BCG remains the most important factor in optimizing survival outcomes in patients with intermediate- and high-risk NMIBC. No significant differences in survival outcomes were observed between full-dose Connaught, Tokyo, and Danish strains. Reduced-dose Connaught strain was associated with the worst survival outcomes. PATIENT SUMMARY: We evaluated the efficacy of different strains and dosages of bacillus Calmette-Guérin (BCG) in patients with intermediate- or high-risk non-muscle-invasive bladder cancer in the past two decades in Hong Kong. We conclude no significant differences in long-term survival outcomes in terms of full-dose Connaught, Tokyo, and Danish strains, while reduced-dose Connaught strain was inferior to the full-dose group. Adequate BCG treatment benefits long-term survival.
AOU Città della Salute e della Scienza di Torino Torino School of Medicine Torino Italy
Department of Experimental and Clinical Biomedical Science University of Florence Florence Italy
Department of Minimally Invasive and Robotic Urology Wrocław Medical University Wrocław Poland
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology La Croix du Sud Hospital Quint Fonsegrives France
Department of Urology MD Anderson Cancer Center Houston TX USA
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology San Raffaele Hospital and Scientific Institute Milan Italy
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Hourani Center of Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Rabin Medical Center Petah Tikva Israel and Medical University of Vienna Austria
School of Life and Medical Sciences University of Hertfordshire Hatfield UK
Unit of Urology Santa Maria della Misericordia Academic Medical Center Udine Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013819
- 003
- CZ-PrNML
- 005
- 20240905134356.0
- 007
- ta
- 008
- 240725s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2023.09.014 $2 doi
- 035 __
- $a (PubMed)37827948
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Liu, Kang $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 245 12
- $a A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer / $c K. Liu, H. Zhao, X. Chen, R. Nicoletti, N. Vasdev, PK. Chiu, CF. Ng, T. Kawada, E. Laukhtina, K. Mori, T. Yanagisawa, D. D'Andrea, M. von Deimling, S. Albisinni, W. Krajewski, B. Pradere, F. Soria, M. Moschini, D. Enikeev, S. Shariat, A. Kamat, G. Giannarini, JY. Teoh, European Association of Urology—Young Academic Urologists Urothelial Carcinoma Working Group
- 520 9_
- $a BACKGROUND: Current European Association of Urology (EAU) guidelines support adjuvant intravesical Bacillus Calmette-Guérin (BCG) treatment after Transurethral Resection of Bladder Tumor (TURB) for intermediate- or high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients, aiming to reduce the risk of tumor recurrence. The quality of data, however, does not allow definitive conclusions on whether different strains and dosages of BCG have different efficacies on long-term survival outcomes. OBJECTIVE: To evaluate the long-term survival outcomes of different strains and dosages of BCG in patients with NMIBC. DESIGN, SETTING, AND PARTICIPANTS: All NMIBC patients treated with intravesical BCG therapy from 2001 to 2020 were identified using a territory-wide database in Hong Kong. INTERVENTION: BCG strains and dosages (Connaught strain 81 mg, Connaught strain 27 mg, Tokyo strain 80 mg, and Danish strain 30 mg) were retrieved from medical records. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. A multivariable Cox regression analysis was used to adjust potential confounding factors, and to estimate Hazard Ratio (HR) and 95% confidence interval (CI) of different BCG strains. A further subgroup analysis on adequate versus inadequate BCG treatment was performed. RESULTS AND LIMITATIONS: A total of 2602 NMIBC patients treated with intravesical BCG were identified. Among them, 1291 (49.6%) received Connaught strain 81 mg, 199 (7.6%) received Connaught strain 27 mg, 1014 (39.0%) received Tokyo strain, and 98 (3.8%) received Danish strain. The median follow-up was 11.0 years. No statistically significant differences in OS, CSS, RFS, and PFS were detected among the different groups. At the multivariable analysis, the Connaught strain 27 mg group was inferior to the Connaught strain 81 mg group in terms of OS (HR: 1.26, 95% CI: 1.05-1.51), CSS (HR: 1.69, 95% CI: 1.08-2.66), and PFS (HR: 1.86, 95% CI: 1.20-2.88). Adequate BCG treatment was associated with improved OS (HR: 0.82, 95% CI: 0.73-0.92), CSS (HR: 0.64, 95% CI: 0.47-0.86), RFS (HR: 0.80, 95% CI: 0.70-0.92), and PFS (HR: 0.52, 95% CI: 0.39-0.68). Among patients treated with adequate BCG, at the multivariable analysis the Connaught strain 27 mg group showed worse results than the Connaught strain 81 mg group in terms of CSS (HR: 1.93, 95% CI: 1.07-3.51). Compared with the Connaught strain 81 mg group, both Tokyo and Danish strains had similar survival outcomes in the whole cohort and the adequate BCG treatment subgroup. CONCLUSIONS: Our findings suggest that adequate BCG remains the most important factor in optimizing survival outcomes in patients with intermediate- and high-risk NMIBC. No significant differences in survival outcomes were observed between full-dose Connaught, Tokyo, and Danish strains. Reduced-dose Connaught strain was associated with the worst survival outcomes. PATIENT SUMMARY: We evaluated the efficacy of different strains and dosages of bacillus Calmette-Guérin (BCG) in patients with intermediate- or high-risk non-muscle-invasive bladder cancer in the past two decades in Hong Kong. We conclude no significant differences in long-term survival outcomes in terms of full-dose Connaught, Tokyo, and Danish strains, while reduced-dose Connaught strain was inferior to the full-dose group. Adequate BCG treatment benefits long-term survival.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $x aplikace a dávkování $7 D000276
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 12
- $a BCG vakcína $x terapeutické užití $x aplikace a dávkování $7 D001500
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 12
- $a nádory močového měchýře neinvadující svalovinu $x mortalita $x terapie $7 D000093284
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a nádory močového měchýře $x mortalita $x terapie $7 D001749
- 651 _2
- $a Hongkong $x epidemiologie $7 D006723
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zhao, Hongda $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Chen, Xuan $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Nicoletti, Rossella $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy
- 700 1_
- $a Vasdev, Nikhil $u Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
- 700 1_
- $a Chiu, Peter Ka-Fung $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Ng, Chi-Fai $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Kawada, Tatsushi $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a D'Andrea, David $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a von Deimling, Markus $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Albisinni, Simone $u Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy
- 700 1_
- $a Krajewski, Wojciech $u Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Soria, Francesco $u AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy
- 700 1_
- $a Moschini, Marco $u Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy
- 700 1_
- $a Enikeev, Dmitry $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Rabin Medical Center, Petah Tikva, Israel and Medical University of Vienna, Austria
- 700 1_
- $a Shariat, Shahrokh $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Kamat, Ashish $u Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Giannarini, Gianluca $u Unit of Urology, Santa Maria della Misericordia Academic Medical Center, Udine, Italy
- 700 1_
- $a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: jeremyteoh@surgery.cuhk.edu.hk
- 710 2_
- $a European Association of Urology—Young Academic Urologists Urothelial Carcinoma Working Group
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 3 (2024), s. 438-446
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37827948 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134350 $b ABA008
- 999 __
- $a ok $b bmc $g 2143560 $s 1225685
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 3 $d 438-446 $e 20231011 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20240725
